Pear Therapeutics: A Successful Product Killed by Operational Failures

Founders love to believe that "product is king." The prevailing wisdom in the valley is simple: build something amazing, get FDA clearance, drive adoption, and the rest will take care of itself.

But the brutal truth is a world-class product with broken operations is just a very expensive hobby. And sometimes, it’s a tragedy.

Such is the story of Pear Therapeutics.

If you look at the surface metrics, Pear had everything a med-tech founder dreams of. They were pioneers in prescription digital therapeutics (PDTs). They had FDA authorization. They had a product that actually worked, helping patients with substance use disorders. Doctors were prescribing it. Patients were using it. The adoption curve was looking exactly like the hockey stick every VC deck promises.

By all traditional measures of "product-market fit," they were beyond successful.

Still, they filed for bankruptcy in the end.

They didn't fail because the tech didn't work. They didn't fail because they couldn't sell. They failed because of a silent killer that bleeds startups dry while everyone is celebrating top-line revenue: Operations Management.

Specifically, they failed the most boring, unsexy part of the business: the revenue cycle.

Let's break this down.

In the US healthcare system, getting a doctor to write a prescription is only half the battle. The other half, the operational half, is getting the insurance company to actually pay for it.

Pear Therapeutics had sales. On paper, they had revenue as well. But they lacked the operational clarity and experience to navigate the labyrinth of insurance claims processing. They were shipping product, incurring costs, and booking sales, but the cash wasn't coming back fast enough to cover the burn.

It’s the classic "cash flow vs. revenue" trap, but on a massive scale.

Reports suggest they had massive difficulties collecting on the prescriptions that were written. They failed to cash insurance claims, and that strangled their cash flow. Think of it as your runway evaporating not because you aren't growing, but because your plumbing is leaking faster than you can pour water in.

The hidden toll? Time. While leadership was likely focused on the next clinical trial or the next big partnership, the operational backlog was compounding by the minute.

The math is unforgiving. You can have 100% year-over-year growth in prescriptions, but if your collection rate lags by months, or if claims are denied because you lack the ops infrastructure to appeal and process them efficiently, you're a dead fish.

We see this pattern more often than we'd like to admit, though rarely is it made public. Founders obsess over their innovations: the code, the clinical data, the marketing, and operations are treated as an afterthought. Ops hires happen too late down the road, when the mess has snowballed and it's difficult to untangle. Even worse: operations are even treated as an administrative burden rather than a strategic engine that can propel the company's growth.

Pear’s leadership had an amazing product. They had fantastic placement. Sales were consistently increasing. But they failed due to a lack of ops clarity and inexperience in the gritty mechanics of reimbursement.

They assumed the system would work if the product was good enough. It didn’t.

Pear Therapeutics' case serves as a warning sign for today's founders: you might have a unique product, but you need to look beyond your product in order to have a sustainable business. You can’t out-innovate a broken business model.

Reflect on your own startup today. You might be hitting your sales targets, but what does your "cash-in-door" timeline look like? Are there operational bottlenecks that are silently strangling your liquidity?

Don't let a lack of operational discipline be the reason your world-changing idea ends up as a bankruptcy headline. Audit your flow. Map the funds, not just the user journey. In the end, cash flow is the only reality that matters.